LSD but not lisuride disrupts prepulse inhibition in rats by activating the 5-HT2A receptor

Psychopharmacology

Volumn 208, Issue 2, 2010, Pages 179-189

  Halberstadt, Adam L ^a   Geyer, Mark A ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

5 HT2A; Hallucinogen; Lisuride; LSD; Prepulse inhibition; Rats

Indexed keywords

DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; GLEMANSERIN; LISURIDE MALEATE; LYSERGIDE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; RACLOPRIDE TARTRATE; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; ALPHA-PHENYL-1-(2-PHENYLETHYL)-4-PIPERIDINEMETHANOL; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; LISURIDE; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE; PSYCHEDELIC AGENT; PYRIDINE DERIVATIVE; RACLOPRIDE; SEROTONIN AGONIST; SEROTONIN ANTAGONIST;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG CLASSIFICATION; DRUG RECEPTOR BINDING; ENZYME ACTIVATION; EXPERIMENTAL DESIGN; MALE; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; RAT; SPRAGUE DAWLEY RAT; STARTLE REFLEX; ANIMAL; ANIMAL BEHAVIOR; AUDITORY STIMULATION; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION;

ACOUSTIC STIMULATION; ANIMALS; BEHAVIOR, ANIMAL; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HALLUCINOGENS; LISURIDE; LYSERGIC ACID DIETHYLAMIDE; MALE; PIPERAZINES; PIPERIDINES; PYRIDINES; RACLOPRIDE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; STARTLE REACTION;

EID: 77449154257     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-009-1718-x     Document Type: Article

References (78)

1. LM Adams MA Geyer 1985 Patterns of exploration in rats distinguish lisuride from lysergic acid diethylamide Pharmacol Biochem Behav 23 461 468 10.1016/0091-3057(85)90022-X 1:CAS:528:DyaL2MXlsFCjsLw%3D 4048241
2. 2A receptors to inhibit NMDA receptor-mediated transmission in the rat prefrontal cortex Eur J NeuroSci 11 3064 3072 10.1046/j.1460-9568.1999. 00726.x 1:STN:280:DyaK1MvktVWhtA%3D%3D 10510170
3. H Beneš A Deissler A Rodenbeck A Engfer R Kohnen 2006 Lisuride treatment of Restless Legs Syndrome: first studies with monotherapy in de novo patients and in combination with levodopa in advanced disease J Neural Transm 113 87 92 10.1007/s00702-005-0386-1 16372146
4. 1C receptor agonist J Pharmacol Exp Ther 258 891 896 1:CAS:528:DyaK3MXlvFyntrY%3D 1679849
5. 2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells Eur J Pharmacol 594 32 38 10.1016/j.ejphar.2008.07.040 1:CAS:528:DC%2BD1cXhtVynurrF 18703043
6. 1C-mediated phenomenon Pharmacol Biochem Behav 48 383 396 10.1016/0091-3057(94)90542-8 1:CAS:528:DyaK2cXkt1Olsrc%3D 8090805
7. 2C receptors Psychopharmacology 136 409 414 10.1007/s002130050585 1:CAS:528:DyaK1cXivFKkt7g%3D 9600588
8. 2C receptors Synapse 35 144 150 10.1002/(SICI)1098-2396(200002)35:2<144::AID- SYN7>3.0.CO;2-K 1:CAS:528:DC%2BD3cXkt1Skug%3D%3D 10611640
9. 2C receptors in the stimulus effects of hallucinogenic drugs I: antagonist correlation analysis Psychopharmacology 121 347 356 10.1007/BF02246074 1:CAS:528:DyaK2MXptVCisLg%3D 8584617
10. D Fiorella RA Rabin JC Winter 1995 Role of 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs. II: reassessment of LSD false positives Psychopharmacology 121 357 363 10.1007/BF02246075 1:CAS:528: DyaK2MXptVCisLk%3D 8584618
11. 2C receptors: evidence favoring the ternary complex and two-state models of agonist action J Neurochem 72 2127 2134 10.1046/j.1471-4159.1999.0722127.x 1:CAS:528:DyaK1MXis12ltLg%3D 10217294
12. EE Garcia RL Smith E Sanders-Bush 2007 Role of Gq protein in behavioral effects of the hallucinogenic drug 1-(2, 5-dimethoxy-4-iodophenyl)-2- aminopropane Neuropharmacology 52 1671 1677 10.1016/j.neuropharm.2007.03.013 1:CAS:528:DC%2BD2sXmtVegs7w%3D 17493641
13. R Gerber BJ Barbaz LL Martin R Neale M Williams JF Liebman 1985 Antagonism of L-5-hydroxytryptophan-induced head-twitching in rats by lisuride: a mixed 5-hydroxytryptamine agonist-antagonist? Neurosci Lett 60 207 213 10.1016/0304-3940(85)90245-9 1:CAS:528:DyaL2MXmtVKnsLo%3D 2997677
14. MA Geyer FX Vollenweider 2008 Serotonin research: contributions to understanding psychoses Trends Pharmacol Sci 29 445 453 10.1016/j.tips.2008.06. 006 1:CAS:528:DC%2BD1cXhtVKnurrN 19086254
15. JC Gillin L Pulvirenti N Withers S Golshan G Koob 1994 The effects of lisuride on mood and sleep during acute withdrawal in stimulant abusers: a preliminary report Biol Psychiatry 35 843 849 10.1016/0006-3223(94)90019-1 1:CAS:528:DyaK2cXlsVyqs7k%3D 8054406
16. 2 agonists or antagonists? Neuropsychopharmacology 3 509 517 1:CAS:528: DyaK3MXkt1Wgtbw%3D 2078284
17. RA Glennon 1991 Discriminative stimulus properties of hallucinogens and related designer drugs NIDA Res Monogr 116 25 44 1:CAS:528:DyaK3sXisVKltbw%3D 1369672
18. RA Glennon AE Hauck 1985 Mechanistic studies on DOM as a discriminative stimulus Pharmacol Biochem Behav 23 937 941 10.1016/0091-3057(85)90096-6 1:CAS:528:DyaL28XotFymtw%3D%3D 2934750
19. 2 involvement in the mechanisms of action of hallucinogenic agents Life Sci 35 2505 2511 10.1016/0024-3205(84)90436-3 1:CAS:528:DyaL2MXlsF2luw%3D%3D 6513725
20. J González-Maeso T Yuen BJ Ebersole E Wurmbach A Lira M Zhou N Weisstaub R Hen JA Gingrich SC Sealfon 2003 Transcriptome fingerprints distinguish hallucinogenic and non-hallucinogenic 5-hydroxytryptamine 2A receptor agonist effects in mouse somatosensory cortex J Neurosci 23 8836 8843 14523084
21. 2A receptor-mediated signaling pathways to affect behavior Neuron 53 439 452 10.1016/j.neuron.2007.01.008 17270739
22. G Gopinathan H Teräväinen JM Dambrosia CD Ward JN Sanes WK Stuart EV Evarts DB Calne 1981 Lisuride in parkinsonism Neurology 31 371 376 1:STN:280:DyaL3M7ntlCnsQ%3D%3D 7194429
23. T Greiner NR Burch R Edelberg 1958 Psychopathology and psychophysiology of minimal LSD-25 dosage; a preliminary dosage-response spectrum AMA Arch Neurol Psychiatry 79 208 210 1:STN:280:DyaG1c%2FktVWhtQ%3D%3D 13497365
24. AL Halberstadt MR Buell VL Masten VB Risbrough MA Geyer 2008 Modification of the effects of 5-methoxy-N, N-dimethyltryptamine on exploratory behavior in rats by monoamine oxidase inhibitors Psychopharmacology 201 55 66 10.1007/s00213-008-1247-z 1:CAS:528:DC%2BD1cXht1GrurbN 18604652
25. 2C receptors exert opposing effects on locomotor activity in mice Neuropsychopharmacology 34 1958 1967 10.1038/npp.2009.29 1:CAS:528:DC%2BD1MXnsFSju70%3D 19322172
26. WM Herrmann R Horowski K Dannehl U Kramer K Lurati 1977 Clinical effectiveness of lisuride hydrogen maleate: a double-blind trial versus methysergide Headache 17 54 60 10.1111/j.1526-4610.1977.hed1702054.x 1:STN:280:DyaE2s7oslaqtQ%3D%3D 324950
27. AM Holohean FJ White JB Appel 1982 Dopaminergic and serotonergic mediation of the discriminable effects of ergot alkaloids Eur J Pharmacol 81 595 602 10.1016/0014-2999(82)90349-1 1:CAS:528:DyaL38Xltl2hsbg%3D 7117388
28. BL Jacobs ME Trulson WC Stern 1977 Behavioral effects of LSD in the cats: proposal of an animal behavioral model for studying the actions of hallucinogenic drugs Brain Res 132 301 314 10.1016/0006-8993(77)90423-1 1:CAS:528:DyaE2sXlvFertL4%3D 19128
29. C Johansson DM Jackson J Zhang L Svensson 1995 Prepulse inhibition of acoustic startle, a measure of sensorimotor gating: effects of antipsychotics and other agents in rats Pharmacol Biochem Behav 52 649 654 10.1016/0091- 3057(95)00160-X 1:CAS:528:DyaK2MXpsVGrsb0%3D 8587900
30. T Kenakin 1995 Agonist-receptor efficacy. II. Agonist trafficking of receptor signals Trends Pharmacol Sci 16 232 238 10.1016/S0165-6147(00)89032-X 1:CAS:528:DyaK2MXnt1Shur4%3D 7667897
31. 2 receptor sites: drug discrimination and receptor binding studies Behav Pharmacol 2 105 112 11224054
32. 2C receptors Neuropsychopharmacology 18 339 351 10.1016/S0893-133X(97)00164-4 1:CAS:528:DyaK1cXit1ehurs%3D 9536447
33. DM Kuhn FJ White JB Appel 1978 The discriminative stimulus properties of LSD: mechanisms of action Neuropharmacology 17 257 263 10.1016/0028-3908(78) 90109-0 1:CAS:528:DyaE1cXlsVSgtLs%3D 652138
34. 2 signaling pathways have different receptor reserves J Pharrmacol Exp Ther 304 229 237 10.1124/jpet.102.042184 1:CAS:528: DC%2BD3sXht1Shtw%3D%3D
35. Leysen JE (1989) Use of 5-HT receptor agonists and antagonists for the characterization of their respective receptor sites. In: Boulton AA, Baker GB, Butterworth R (eds) Drugs as tools in neurotransmitter research. Neuromethods, vol 12. Springer, Berlin, pp 299-350
36. A Lieberman M Goldstein A Neophytides M Kupersmith M Leibowitz N Zasorin R Walker D Kleinberg 1981 Lisuride in Parkinson disease: efficacy of lisuride compared to levodopa Neurology 31 961 965 1:STN:280:DyaL3M3ntFWkug%3D%3D 7022259
37. AN Lieberman G Gopinathan A Neophytides M Leibowitz R Walker E Hiesiger 1983 Bromocriptine and lisuride in Parkinson disease Ann Neurol 13 44 47 10.1002/ana.410130110 1:STN:280:DyaL3s7ltFensg%3D%3D 6830164
38. A Liuzzi PG Chiodini G Oppizzi L Botalla G Verde L De Stefano G Colussi KJ Gräf R Horowski 1978 Lisuride hydrogen maleate: Evidence for a long lasting dopaminergic activity in humans J Clin Endocrinol Metab 46 196 202 10.1210/jcem-46-2-196 1:CAS:528:DyaE1cXhvVeit70%3D 108287
39. RS Mansbach MA Geyer DL Braff 1988 Dopaminergic stimulation disrupts sensorimotor gating in the rat Psychopharmacology 94 507 514 10.1007/BF00212846 1:CAS:528:DyaL1cXktVCktbs%3D 3131796
40. JL Marini BL Jacobs MH Sheard ME Trulson 1981 Activity of a non-hallucinogenic ergoline derivative, lisuride, in an animal behavior model for hallucinogens Psychopharmacology 73 328 331 10.1007/BF00426460 1:CAS:528:DyaL3MXktlGmtbg%3D 6789353
41. 1A receptor-mediated behavioral effects overlap its other properties in rats Psychopharmacology 164 93 107 10.1007/s00213-002-1141-z 1:CAS:528:DC%2BD38Xns1Ogtr8%3D 12373423
42. D Marona-Lewicka BR Chemel DE Nichols 2009 Dopamine D4 receptor involvement in the discriminative stimulus effects in rats of LSD, but not the phenethylamine hallucinogen DOI Psychopharmacology 203 265 277 10.1007/s00213-008-1238-0 1:CAS:528:DC%2BD1MXivFWgt7Y%3D 18604600
43. RB McCall GK Aghajanian 1980 Hallucinogens potentiate responses to serotonin and norepinephrine in the facial motor nucleus Life Sci 26 1149 1156 10.1016/0024-3205(80)90654-2 1:CAS:528:DyaL3cXktVSktLY%3D 7392793
44. MJ Millan L Maiofiss D Cussac V Audinot JA Boutin A Newman-Tancredi 2002 Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding properties of 14 drugs at 21 native and cloned human receptor subtypes J Pharmacol Exp Ther 303 791 804 10.1124/jpet.102.039867 1:CAS:528:DC%2BD38XotlCnsL8%3D 12388666
45. 2-adrenoceptor J Pharmacol Exp Ther 303 805 814 10.1124/jpet.102. 039875 1:CAS:528:DC%2BD38XotlCnsLw%3D 12388667
46. 2, receptor subtypes J Pharmacol Exp Ther 303 815 822 10.1124/jpet.102.039883 1:CAS:528:DC%2BD38XotlCnsL0%3D 12388668
47. DE Nichols CD Nichols 2008 Serotonin receptors Chem Rev 108 1614 1641 10.1021/cr078224o 1:CAS:528:DC%2BD1cXlslOisL8%3D 18476671
48. DE Nichols S Frescas D Marona-Lewicka DM Kurrasch-Orbaugh 2002 Lysergamides of isomeric 2, 4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N, N-diethyllysergamide (LSD) J Med Chem 45 4344 4349 10.1021/jm020153s 1:CAS:528:DC%2BD38Xms1Kqtb8%3D 12213075
49. A Ouagazzal AJ Grottick J Moreau GA Higgins 2001 Effect of LSD on prepulse inhibition and spontaneous behavior in the rat. A pharmacological analysis and comparison between two rat strains Neuropsychopharmacology 25 565 575 10.1016/S0893-133X(01)00282-2 1:CAS:528:DC%2BD3MXms12mt70%3D 11557170
50. JD Parkes M Schachter CD Marsden B Smith A Wilson 1981 Lisuride in parkinsonism Ann Neurol 9 48 52 10.1002/ana.410090109 1:STN:280: DyaL3M7lvVOhsA%3D%3D 7212665
51. 3 receptor-preferring agonist: comparison to other dopamine receptor agonists Eur J Pharmacol 312 35 44 10.1016/0014-2999(96)00454-2 1:CAS:528:DyaK28Xls1Kmt74%3D 8891576
52. M Pieri R Schaffner L Pieri M Da Prada W Haefely 1978 Turning in MFB-lesioned rats and antagonism of neuroleptic-induced catalepsy after lisuride and LSD Life Sci 22 1615 1622 10.1016/0024-3205(78)90057-7 1:CAS:528: DyaE1cXkvVCksrg%3D 307642
53. 2A receptor-stimulated phosphoinositide hydrolysis in the stimulus effects of hallucinogens Pharmacol Biochem Behav 72 29 37 10.1016/S0091-3057(01)00720-1 1:CAS:528:DC%2BD38XitFWltrg%3D 11900766
54. E Raffaelli Jr OJ Martins P dos Santos A Dãgua Filho 1983 Lisuride in cluster headache Headache 23 117 121 6874328
55. 2 receptor: implications for treating LSD-induced hallucinogenesis Psychopharmacology 98 495 499 10.1007/BF00441948 1:CAS:528:DyaL1MXlvVOhu7g%3D 2505289
56. 1C receptor agonists: what next? NIDA Res Monogr 146 203 213 1:STN:280:DyaK283ps1Wluw%3D%3D 8742800
57. M Schachter J Blackstock JP Dick RJ George CD Marsden JD Parkes 1979 Lisuride in Parkinson's disease Lancet 2 8152 1129 10.1016/S0140-6736(79)92523-6 1:STN:280:DyaL3c%2FltlKqsQ%3D%3D 91855
58. LG Schmidt S Kuhn M Smolka K Schmidt H Rommelspacher 2002 Lisuride, a dopamine D2 receptor agonist, and anticraving drug expectancy as modifiers of relapse in alcohol dependence Prog Neuropsychopharmacol Biol Psychiatry 26 209 217 10.1016/S0278-5846(01)00214-7 1:CAS:528:DC%2BD38XlvFOrtg%3D%3D 11817496
59. R Schreiber M Brocco MJ Millan 1994 Blockade of the discriminative stimulus effect of DOI by MDL 100, 907 and the 'atypical' antipsychotics, clozapine and risperidone Eur J Pharmacol 264 99 102 10.1016/0014-2999(94)90643- 2 1:CAS:528:DyaK2cXmvFamsLo%3D 7530204
60. R Schreiber M Brocco V Audinot A Gobert S Veiga MJ Millan 1995 (1-(2, 5-Dimethoxy-4 iodophenyl)-2-aminopropane)-induced head-twitches in the rat are mediated by 5-hydroxytryptamine (5-HT) 2A receptors: modulation by novel 5-HT2A/2C antagonists, D1 antagonists and 5-HT1A agonists J Pharmacol Exp Ther 273 101 112 1:CAS:528:DyaK2MXltVGlt7s%3D 7714755
61. TE Sipes MA Geyer 1994 Multiple serotonin receptor subtypes modulate prepulse inhibition of the startle response in rats Neuropharmacology 33 441 448 10.1016/0028-3908(94)90074-4 1:CAS:528:DyaK2cXjtFKms7Y%3D 7984282
62. TE Sipes MA Geyer 1995 8-OH-DPAT disruption of prepulse inhibition in rats: reversal with (+)WAY 100, 135 and localization of site of action Psychopharmacology 117 41 48 10.1007/BF02245096 1:CAS:528:DyaK2MXkslSis74%3D 7724701
63. 2C receptors Behav Pharmacol 6 839 842 10.1097/00008877-199512000-00010 1:CAS:528:DyaK28XhtVSgtbg%3D 11224388
64. BW Somerville WM Herrmann 1978 Migraine prophylaxis with Lisuride hydrogen maleate-a double blind study of Lisuride versus placebo Headache 18 75 79 10.1111/j.1526-4610.1978.hed1802075.x 1:STN:280:DyaE1c7ntFSgtA%3D%3D 348647
65. WA Stoll 1949 Ein neues, in sehr kleinen mengen wirksames phantastikum Schweiz Arch neurol 64 483 484
66. 2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens Psychopharmacology 94 213 216 10.1007/BF00176847 1:CAS:528:DyaL1cXhs1Whtbs%3D 3127847
67. J Vaamonde MR Luquin JA Obeso 1991 Subcutaneous lisuride infusion in Parkinson's disease. Response to chronic administration in 34 patients Brain 114 Pt 1B 601 617 10.1093/brain/114.1.601 2004258
68. ML Vance WS Evans MO Thorner 1984 Drugs five years later. Bromocriptine Ann Intern Med 100 78 91 1:STN:280:DyaL2c7gt1Ogsg%3D%3D 6229205
69. G Verde PG Chiodini A Liuzzi R Cozzi F Favales L Botalla B Spelta D Dalla Bonzana E Rainer R Horowski 1980 Effectiveness of the dopamine agonist lisuride in the treatment of acromegaly and pathological hyperprolactinemic states J Endocrinol Invest 3 405 414 1:STN:280:DyaL3M7ktlejtA%3D%3D 6782153
70. 2C receptor agonists Pharmacol Biochem Behav 69 643 652 10.1016/S0091-3057(01)00552-4 1:CAS:528:DC%2BD3MXlvFWrsLY%3D 11509227
71. FX Vollenweider MFI Vollenweider-Scherpenhuyzen A Bäbler H Vogel D Hell 1998 Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action NeuroReport 9 3897 3902 10.1097/00001756-199812010- 00024 1:CAS:528:DyaK1MXjtVCitQ%3D%3D 9875725
72. FX Vollenweider PA Csomor B Knappe MA Geyer BB Quednow 2007 The effects of the preferential 5-HT2A agonist psilocybin on prepulse inhibition of startle in healthy human volunteers depend on interstimulus interval Neuropsychopharmacology 32 1876 1887 10.1038/sj.npp.1301324 1:CAS:528: DC%2BD2sXptVWis78%3D 17299516
73. 1 dopamine receptors Psychopharmacology 118 401 409 10.1007/BF02245940 1:CAS:528: DyaK2MXmtVensbg%3D 7568626
74. FJ White JB Appel 1982 Lysergic acid diethylamide (LSD) and lisuride: differentiation of their neuropharmacological actions Science 216 535 537 10.1126/science.7071600 1:CAS:528:DyaL38XitFSrtLY%3D 7071600
75. FJ White RY Wang 1983 Comparison of the effects of LSD and lisuride on A10 dopamine neurons in the rat Neuropharmacology 22 669 676 10.1016/0028-3908(83)90089-8 1:CAS:528:DyaL3sXltFGqsrY%3D 6888664
76. FJ White RY Wang 1984 Pharmacological characterization of dopamine autoreceptors in the rat ventral tegmental area: microiontophoretic studies J Pharmacol Exp Ther 231 275 280 1:CAS:528:DyaL2MXhvVamsg%3D%3D 6491980
77. FJ White AM Holohean JB Appel 1981 Lack of specificity of an animal behavior model for hallucinogenic drug action Pharmacol Biochem Behav 14 330 343 10.1016/0091-3057(81)90400-7
78. M Yamaguchi K Kimura-Iwasaki T Akai Y Nakada H Nakagawa 1991 Terguride, a dopamine D(2) partial agonist, as a discriminative stimulus in rats Behav Pharmacol 2 233 240 10.1097/00008877-199106000-00007 11224067